Marina Biotech (formerly MDRNA/Nastech) is offering intellectual property related to intranasal formulations of rapid-acting insulin and of parathyroid hormone (PTH) for the treatment of osteoporosis for sale through ICAP Patent Brokerage. ICAP has recently handled a number of portfolios related to inhalation and nasal delivery, offering several at live auction in March 2011.
J. Michael French, CEO of Marina Biotech explained, “Our intranasal insulin program, originally positioned to serve a diabetic patient population, holds additional promise in the potential treatment of CNS diseases such as Alzheimer’s. Our proprietary formulation may provide distinct therapeutic advantages over other intranasal delivered insulin compounds.”
According to information about the formulations provided by ICAP, Phase 1 and Phase 2 clinical trials have been completed, and data have shown that the intranasal insulin has “very rapid PK profile” and is well tolerated. The intranasal formulation of regular insulin is stable at room temperature.
The ICAP press release does not address the portfolio of intranasal PTH technology; the company’s web site says that it is “a Phase III-Ready Program.”
Read the ICAP press release.
